Suppression of eltoprazine-induced REM sleep rebound by scopolamine

Robert Stickgold, Julie Williams, Subimal Datta, James Quattrochi, J. Allan Hobson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Previous studies have demonstrated that REM sleep suppression produced by the serotonin1 agonist eltoprazine (1 mg/kg b.i.d., administered i.p.) is followed by a dramatic rebound in REM sleep. In the present study, cats were treated with scopolamine (2 mg/kg b.i.d.) after 3 days of eltoprazine-induced REM sleep suppression. During scopolamine treatment, the percentage of REM sleep (9.9±3.5%) was well below baseline levels (13.7±1.6%; P<0.05). Even after the 3-day scopolamine treatment ended, the subsequent REM sleep rebound after the combined eltoprazine-scopolamine treatment (16.8±2.8% REM sleep during 3-day rebound; P<0.10 compared to baseline) was less than a third of the rebound normally seen after eltoprazine. These results provide evidence for the reciprocal relationship between acetylcholine and serotonin and suggest a new set-point model for the mechanism of REM sleep regulation and rebound.

Original languageEnglish (US)
Pages (from-to)447-453
Number of pages7
JournalNeuropharmacology
Volume32
Issue number5
DOIs
StatePublished - Jan 1 1993

Fingerprint

Scopolamine Hydrobromide
REM Sleep
eltoprazine
Acetylcholine
Serotonin
Cats
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Suppression of eltoprazine-induced REM sleep rebound by scopolamine. / Stickgold, Robert; Williams, Julie; Datta, Subimal; Quattrochi, James; Allan Hobson, J.

In: Neuropharmacology, Vol. 32, No. 5, 01.01.1993, p. 447-453.

Research output: Contribution to journalArticle

Stickgold, R, Williams, J, Datta, S, Quattrochi, J & Allan Hobson, J 1993, 'Suppression of eltoprazine-induced REM sleep rebound by scopolamine', Neuropharmacology, vol. 32, no. 5, pp. 447-453. https://doi.org/10.1016/0028-3908(93)90168-3
Stickgold, Robert ; Williams, Julie ; Datta, Subimal ; Quattrochi, James ; Allan Hobson, J. / Suppression of eltoprazine-induced REM sleep rebound by scopolamine. In: Neuropharmacology. 1993 ; Vol. 32, No. 5. pp. 447-453.
@article{000e6528f75446eb96934d12d712d078,
title = "Suppression of eltoprazine-induced REM sleep rebound by scopolamine",
abstract = "Previous studies have demonstrated that REM sleep suppression produced by the serotonin1 agonist eltoprazine (1 mg/kg b.i.d., administered i.p.) is followed by a dramatic rebound in REM sleep. In the present study, cats were treated with scopolamine (2 mg/kg b.i.d.) after 3 days of eltoprazine-induced REM sleep suppression. During scopolamine treatment, the percentage of REM sleep (9.9±3.5{\%}) was well below baseline levels (13.7±1.6{\%}; P<0.05). Even after the 3-day scopolamine treatment ended, the subsequent REM sleep rebound after the combined eltoprazine-scopolamine treatment (16.8±2.8{\%} REM sleep during 3-day rebound; P<0.10 compared to baseline) was less than a third of the rebound normally seen after eltoprazine. These results provide evidence for the reciprocal relationship between acetylcholine and serotonin and suggest a new set-point model for the mechanism of REM sleep regulation and rebound.",
author = "Robert Stickgold and Julie Williams and Subimal Datta and James Quattrochi and {Allan Hobson}, J.",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/0028-3908(93)90168-3",
language = "English (US)",
volume = "32",
pages = "447--453",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Suppression of eltoprazine-induced REM sleep rebound by scopolamine

AU - Stickgold, Robert

AU - Williams, Julie

AU - Datta, Subimal

AU - Quattrochi, James

AU - Allan Hobson, J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Previous studies have demonstrated that REM sleep suppression produced by the serotonin1 agonist eltoprazine (1 mg/kg b.i.d., administered i.p.) is followed by a dramatic rebound in REM sleep. In the present study, cats were treated with scopolamine (2 mg/kg b.i.d.) after 3 days of eltoprazine-induced REM sleep suppression. During scopolamine treatment, the percentage of REM sleep (9.9±3.5%) was well below baseline levels (13.7±1.6%; P<0.05). Even after the 3-day scopolamine treatment ended, the subsequent REM sleep rebound after the combined eltoprazine-scopolamine treatment (16.8±2.8% REM sleep during 3-day rebound; P<0.10 compared to baseline) was less than a third of the rebound normally seen after eltoprazine. These results provide evidence for the reciprocal relationship between acetylcholine and serotonin and suggest a new set-point model for the mechanism of REM sleep regulation and rebound.

AB - Previous studies have demonstrated that REM sleep suppression produced by the serotonin1 agonist eltoprazine (1 mg/kg b.i.d., administered i.p.) is followed by a dramatic rebound in REM sleep. In the present study, cats were treated with scopolamine (2 mg/kg b.i.d.) after 3 days of eltoprazine-induced REM sleep suppression. During scopolamine treatment, the percentage of REM sleep (9.9±3.5%) was well below baseline levels (13.7±1.6%; P<0.05). Even after the 3-day scopolamine treatment ended, the subsequent REM sleep rebound after the combined eltoprazine-scopolamine treatment (16.8±2.8% REM sleep during 3-day rebound; P<0.10 compared to baseline) was less than a third of the rebound normally seen after eltoprazine. These results provide evidence for the reciprocal relationship between acetylcholine and serotonin and suggest a new set-point model for the mechanism of REM sleep regulation and rebound.

UR - http://www.scopus.com/inward/record.url?scp=0027254034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027254034&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(93)90168-3

DO - 10.1016/0028-3908(93)90168-3

M3 - Article

VL - 32

SP - 447

EP - 453

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 5

ER -